hepatocellular carcinoma
Conditions
Interventions
A:transarterial chemoembolization
B:Transarterial Chemoembolization (TACE) with Sequential Cryoablation
Sponsors
The First Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. CT, MRI and AFP combined with clinical or pathological diagnosis of hepatocellular carcinoma; 2. Prior informed consent; Be able to follow the visit/treatment rules according to the research programs; 3. Generally in good condition, adequate bone marrow, liver and renal function; 4. ECOG Performance Status of 0-2; 5. Advanced stage HCC/ BCLC B stage; 6. Hepatitis B history or HBsAg positive; 7. Patients without previously surgery, local-regional therapies (radiofrequency ablation, et al), or liver transplantation; 8. Aged 18 to 65 years; 9. Child Pugh class A/B (== 100*10^9/L; ALT and AST =30g/L; Total bilirubin =<34 mmol/L.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Extrahepatic metastasis, or tumor thrombosis invasive venous system; 3. Any contraindications for hepatic embolization procedures(known renal failure/insufficiency requiring hemo-or peritoneal dialysis); 4. Patients with prior malignancy were ineligible for the study, with the exception of those who had been disease free for longer than 5 years; 5. Patients with liver transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3year overall survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to progression;distant metastasis rate; | — |
Countries
China
Contacts
Public ContactJia-ping Li
Outcome results
None listed